License agreement

Map of Europe
#CNS #Collaboration #European Medicines Agency #License agreement #Orphan drugs

Alliance will provide a new therapy for rare CNS disease 

Minoryx and Neuraxpharm have agreed a strategic alliance to provide a new therapy for rare CNS disease patients in Europe.  The companies have entered into a license agreement for the European rights to leriglitazone, currently under European Medicines Agency (EMA) review for the orphan indication X-linked Adrenoleukodystrophy… Read More

#News